About AbSci
AbSci is a company based in Vancouver (United States) founded in 2011.. AbSci has raised $227.56 million across 7 funding rounds from investors including Fidelity Investments, AGC and KBI Biopharma. The company has 157 employees as of December 31, 2024. AbSci has completed 2 acquisitions, including Denovium and Totient. AbSci offers products and services including Drug Creation Platform and AI Target Discovery. AbSci operates in a competitive market with competitors including LabGenius, Ordaos, immunitoAI, Enpicom and Alkira Bio, among others.
- Headquarter Vancouver, United States
- Employees 157 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Absci Corporation
-
Annual Revenue
$4.53 M-20.71as on Dec 31, 2024
-
Net Profit
$-103.11 M6.75as on Dec 31, 2024
-
EBITDA
$-95.5 M-19.85as on Dec 31, 2024
-
Total Equity Funding
$227.56 M (USD)
in 7 rounds
-
Latest Funding Round
$125 M (USD), Series E
Mar 23, 2021
-
Investors
Fidelity Investments
& 15 more
-
Employee Count
157
as on Dec 31, 2024
-
Investments & Acquisitions
Denovium
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AbSci
AbSci is a publicly listed company on the NASDAQ with ticker symbol ABSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AbSci
AbSci offers a comprehensive portfolio of products and services, including Drug Creation Platform and AI Target Discovery. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Integrates AI for biologics design and optimization in drug development.
Uses reverse immunology to find novel targets for antibody optimization.
Unlock access to complete
Unlock access to complete
Funding Insights of AbSci
AbSci has successfully raised a total of $227.56M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series E — $125.0M
-
First Round
First Round
(11 Apr 2016)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series E - AbSci | Valuation | Casdin Capital , Redmile Group | |
| Oct, 2020 | Amount | Series E - AbSci | Valuation | Casdin Capital | |
| Jan, 2020 | Amount | Debt – Conventional - AbSci | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AbSci
AbSci has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, AGC and KBI Biopharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Founded Year | Domain | Location | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AbSci
AbSci has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Denovium and Totient. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI methods and solutions are provided to the biopharma industry.
|
2018 | ||||
|
Developer of a drug discovery platform for cancer and autoimmune disease by using artificial intelligence
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - AbSci
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Absci Comparisons
Competitors of AbSci
AbSci operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LabGenius, Ordaos, immunitoAI, Enpicom and Alkira Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven platform for discovering and optimizing therapeutic antibodies for treatments.
|
|
| domain | founded_year | HQ Location |
AI accelerator provided for biomedical research and drug discovery.
|
|
| domain | founded_year | HQ Location |
An AI-based platform for antibody discovery and therapeutics is developed.
|
|
| domain | founded_year | HQ Location |
Developer of bioinformatics platform integrating data, automation, and AI for biologics
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies targeting complex membrane proteins are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Absci
Frequently Asked Questions about AbSci
When was AbSci founded?
AbSci was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Where is AbSci located?
AbSci is headquartered in Vancouver, United States. It is registered at Vancouver, Washington, United States.
Is AbSci a funded company?
AbSci is a funded company, having raised a total of $227.56M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $5M, raised on Apr 11, 2016.
How many employees does AbSci have?
As of Dec 31, 2024, the latest employee count at AbSci is 157.
What is the annual revenue of AbSci?
Annual revenue of AbSci is $4.53M as on Dec 31, 2024.
What does AbSci do?
AbSci was founded in 2011 and is based in Vancouver, United States. An integrated platform is offered in the biotechnology sector, where biologic drug discovery and cell line development are combined into one process. Recombinant proteins for therapeutic uses are produced through AI-driven methods. This approach supports the generation of novel biologics, with operations centered on advancing protein engineering for medical applications.
Who are the top competitors of AbSci?
AbSci's top competitors include Ordaos, immunitoAI and Enpicom.
What products or services does AbSci offer?
AbSci offers Drug Creation Platform and AI Target Discovery.
Is AbSci publicly traded?
Yes, AbSci is publicly traded on NASDAQ under the ticker symbol ABSI.
How many acquisitions has AbSci made?
Who are AbSci's investors?
AbSci has 16 investors. Key investors include Fidelity Investments, AGC, KBI Biopharma, Perceptive Advisors, and ArrowMark Partners.
What is AbSci's ticker symbol?
The ticker symbol of AbSci is ABSI on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.